Opportunity Information: Apply for PAR 12 297
Apply for PAR 12 297
- The National Institutes of Health in the education health sector is offering a public funding opportunity titled "Mechanism for Time Sensitive Drug Abuse Research (R21)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.279 Drug Abuse and Addiction Research Programs.
- This funding opportunity was created on Sep 26, 2012 and posted on Sep 26, 2012.
- Applicants must submit their applications by Dec 9, 2015. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Each selected applicant is eligible to receive up to $200,000.00 in funding.
- Eligible applicants include: Special district governments For profit organizations other than small businesses Native American tribal governments (Federally recognized) County governments Public housing authorities/Indian housing authorities Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education State governments City or township governments Native American tribal organizations (other than Federally recognized tribal governments) Independent school districts Others (see text field entitled Additional Information on Eligibility for clarification) Public and State controlled institutions of higher education Small businesses Private institutions of higher education Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education.
- Other Eligible Applicants include the following Alaska Native and Native Hawaiian Serving Institutions Asian American Native American Pacific Islander Serving Institutions (AANAPISISs) Eligible Agencies of the Federal Government Faith based or Community based Organizations Hispanic serving Institutions Historically Black Colleges and Universities (HBCUs) Indian/Native American Tribal Governments (Other than Federally Recognized) Regional Organizations Tribally Controlled Colleges and Universities (TCCUs) U.S. Territory or Possession Non domestic (non U.S.) Entities (Foreign Institutions) are not eligible to apply. Non domestic (non U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are not allowed.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The Mechanism for Time Sensitive Drug Abuse Research (R21), Funding Opportunity Number PAR-12-297, is a National Institute on Drug Abuse (NIDA) program under the National Institutes of Health (NIH) designed to fund rapid, short-term studies when a brief window of opportunity exists to answer an important drug abuse research question. The core idea is that certain developments in health systems, public health, policy, or criminal justice can change quickly, and if researchers cannot collect data or launch an evaluation right away, the chance to learn from that real-world event may disappear. Because of that, applications must make a convincing case that the research is genuinely time sensitive and that expedited review and funding are necessary to capture perishable information.
This announcement uses the NIH R21 mechanism, which is typically aimed at pilot, feasibility, or exploratory research rather than large, definitive trials. Projects can run for up to two years, and the listed award ceiling is $200,000. The intention is to support focused studies that can be initiated quickly, generate early evidence, and inform next steps such as larger NIH applications, policy decisions, or rapid improvements in service delivery. While the FOA supports a broad range of approaches, it is especially suited to designs that can take advantage of natural experiments, rapid implementation studies, fast-moving surveillance and trend analyses, short prospective cohorts, or evaluations tied to sudden system changes.
NIDA identifies four priority areas for these time sensitive opportunities. First, it encourages research that responds to unexpected and time sensitive medical system issues, such as sudden changes in how addiction treatment is delivered within a shifting health care environment. Second, it supports rapid responses to emerging drug abuse-related HIV trends and topics, including quickly evolving epidemics or time sensitive policy and environmental changes that may affect HIV risk among people who use drugs. Third, it targets unexpected and time sensitive criminal justice opportunities, such as new system-level or structural changes that influence drug use outcomes, access to care, or the delivery of health services for justice-involved populations. Fourth, it invites rapid studies of unexpected and time sensitive prescription drug abuse opportunities, for example new state or local initiatives that may affect prescribing, diversion, misuse, or treatment access. Across all four areas, the emphasis is on acting quickly to learn from changes as they happen, rather than studying them long after the fact.
Eligibility is broad and includes many types of U.S.-based organizations and governments. Eligible applicants include public and private institutions of higher education, nonprofits (including those with and without 501(c)(3) status, with the latter excluding institutions of higher education), for-profit organizations (including small businesses), and a wide range of government entities such as state, county, city or township governments, special district governments, independent school districts, and public housing authorities/Indian housing authorities. Tribal governments and tribal organizations are eligible, including federally recognized tribal governments and other tribal entities, as well as tribally controlled colleges and universities. The FOA also explicitly notes eligibility for organizations such as Historically Black Colleges and Universities (HBCUs), Hispanic-serving institutions, Alaska Native and Native Hawaiian Serving Institutions, and Asian American Native American Pacific Islander Serving Institutions, along with faith-based or community-based organizations and regional organizations. Foreign institutions are not eligible, and foreign components of U.S. organizations are not allowed, consistent with NIH policy as referenced in the announcement.
Administratively, this is a discretionary grant opportunity in the health and education activity area, linked to CFDA 93.279 (Drug Abuse and Addiction Research Programs), and it does not require cost sharing or matching. The opportunity was posted on September 26, 2012, and the original and current closing date listed is December 9, 2015, with an archive date of January 9, 2016, meaning it is no longer an active open solicitation in this exact form, but it remains useful as a reference point for how NIDA structures rapid-response research mechanisms. The full announcement was available through the NIH grants guide (as provided in the link), and the contact listed for access or linking issues is the NIH Office of Extramural Research (OER) webmaster.
Frequently Asked Questions (FAQs)
1) What is the Mechanism for Time Sensitive Drug Abuse Research (R21) (PAR-12-297)?
It is a National Institute on Drug Abuse (NIDA) funding opportunity under the National Institutes of Health (NIH) intended to support rapid, short-term drug abuse research studies when there is a brief window of opportunity to answer an important question. The focus is on capturing information that could be lost if research does not start quickly.
2) What does "time sensitive" mean in this funding opportunity?
"Time sensitive" refers to situations where real-world developments in health systems, public health, policy, or criminal justice are changing quickly, and the opportunity to collect data or evaluate effects may disappear if researchers cannot act immediately. Applications are expected to make a convincing case that the information is perishable and that expedited review and funding are needed.
3) What is the overall purpose of this program?
The purpose is to fund focused, quickly initiated studies that can generate early evidence from fast-moving real-world changes, helping inform next research steps (including larger NIH applications), policy decisions, or rapid improvements in service delivery.
4) What grant mechanism does this opportunity use?
This announcement uses the NIH R21 mechanism, which is generally intended for pilot, feasibility, or exploratory research rather than large, definitive trials.
5) How long can an R21 project last under this opportunity?
Projects can run for up to two years.
6) What is the maximum award amount mentioned for this opportunity?
The listed award ceiling is $200,000.
7) What kinds of research designs or approaches are especially suited to this FOA?
The FOA is described as particularly suited to natural experiments, rapid implementation studies, fast-moving surveillance and trend analyses, short prospective cohorts, or evaluations tied to sudden system changes.
8) What makes an application competitive under this time-sensitive concept?
Based on the description, a key factor is whether the application convincingly demonstrates that the research question is genuinely time sensitive and that expedited review and funding are necessary to capture perishable information tied to a real-world event or rapid change.
9) What are the four priority areas NIDA identifies for time sensitive opportunities?
NIDA identifies four priority areas: (1) unexpected and time sensitive medical system issues, (2) emerging drug abuse-related HIV trends and topics, (3) unexpected and time sensitive criminal justice opportunities, and (4) unexpected and time sensitive prescription drug abuse opportunities.
10) What is included in the "medical system issues" priority area?
This area includes rapid-response research tied to unexpected and time sensitive issues in medical systems, such as sudden changes in how addiction treatment is delivered within a shifting health care environment.
11) What is included in the HIV-related priority area?
This area supports rapid responses to emerging drug abuse-related HIV trends and topics, including quickly evolving epidemics or time sensitive policy and environmental changes that may affect HIV risk among people who use drugs.
12) What is included in the criminal justice priority area?
This area targets unexpected and time sensitive opportunities arising from criminal justice system-level or structural changes that influence drug use outcomes, access to care, or delivery of health services for justice-involved populations.
13) What is included in the prescription drug abuse priority area?
This area invites rapid studies tied to unexpected and time sensitive prescription drug abuse opportunities, such as new state or local initiatives that may affect prescribing, diversion, misuse, or treatment access.
14) Is this program intended for long, multi-year definitive trials?
No. The announcement describes the R21 mechanism as typically aimed at pilot, feasibility, or exploratory research rather than large, definitive trials, and it emphasizes short-term studies that can be initiated quickly.
15) What types of organizations are eligible to apply?
Eligibility is broad and includes many U.S.-based organizations and governments. The description lists public and private institutions of higher education, nonprofits (with and without 501(c)(3) status, with the latter excluding institutions of higher education), for-profit organizations (including small businesses), and many government entities (such as state, county, city or township governments, special districts, independent school districts, and public housing authorities/Indian housing authorities).
16) Are tribal governments and tribal organizations eligible?
Yes. The description states that federally recognized tribal governments and other tribal entities are eligible, along with tribal organizations and tribally controlled colleges and universities.
17) Are certain institution types explicitly mentioned as eligible?
Yes. The FOA explicitly notes eligibility for organizations such as Historically Black Colleges and Universities (HBCUs), Hispanic-serving institutions, Alaska Native and Native Hawaiian Serving Institutions, and Asian American Native American Pacific Islander Serving Institutions. It also mentions faith-based or community-based organizations and regional organizations.
18) Are foreign institutions eligible to apply?
No. Foreign institutions are not eligible under this announcement.
19) Are foreign components of U.S. organizations allowed?
No. Foreign components of U.S. organizations are not allowed, consistent with NIH policy as referenced in the announcement.
20) Is cost sharing or matching required?
No. The opportunity does not require cost sharing or matching.
21) What is the CFDA number associated with this opportunity?
It is linked to CFDA 93.279 (Drug Abuse and Addiction Research Programs).
22) What activity area is this opportunity associated with?
It is described as a discretionary grant opportunity in the health and education activity area.
23) When was this opportunity posted, and what were the key dates listed?
The opportunity was posted on September 26, 2012. The original and current closing date listed is December 9, 2015, and the archive date is January 9, 2016.
24) Is PAR-12-297 currently an open solicitation?
No. Based on the closing and archive dates provided (closing date December 9, 2015; archive date January 9, 2016), it is no longer an active open solicitation in this exact form.
25) Why might this FOA still be useful if it is archived?
The description notes that it remains useful as a reference point for how NIDA structures rapid-response research mechanisms, even though it is not currently open in that exact form.
26) Where was the full announcement available?
The full announcement was available through the NIH grants guide (via the link referenced in the source description).
27) Who is listed as the contact for access or linking issues?
The contact listed for access or linking issues is the NIH Office of Extramural Research (OER) webmaster.
Browse more opportunities from the same agency: National Institutes of Health
Browse more opportunities from the same category: Education Health
Next opportunity: Cancer Center Support Grants (CCSGs) for NCI designated Cancer Centers (P30)
Previous opportunity: Industrial Zone Development
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for PAR 12 297
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (PAR 12 297) also looked into and applied for these:
| Funding Opportunity |
|---|
| Cancer Center Support Grants (CCSGs) for NCI designated Cancer Centers (P30) Apply for PAR 12 298 Funding Number: PAR 12 298 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| FY 2013 American Schools and Hospitals Abroad (ASHA) Program Worldwide Apply for APS ASHA 13 000001 Funding Number: APS ASHA 13 000001 Agency: Agency for International Development Category: Education Health Funding Amount: $2,000,000 |
| NLM Grants for Scholarly Works in Biomedicine and Health (G13) Apply for PAR 13 014 Funding Number: PAR 13 014 Agency: National Institutes of Health Category: Education Health Funding Amount: $50,000 |
| Prescription Drug Abuse (R01) Apply for PA 13 015 Funding Number: PA 13 015 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Prescription Drug Abuse (R21) Apply for PA 13 016 Funding Number: PA 13 016 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Early Stage Innovative Molecular Analysis Technology Development for Cancer Research (R21) Apply for RFA CA 13 001 Funding Number: RFA CA 13 001 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Validation and Advanced Development of Emerging Molecular Analysis Technologies for Cancer Research (R33) Apply for RFA CA 13 002 Funding Number: RFA CA 13 002 Agency: National Institutes of Health Category: Education Health Funding Amount: $300,000 |
| Early Stage Development of Innovative Technologies for Biospecimen Science (R21) Apply for RFA CA 13 003 Funding Number: RFA CA 13 003 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Validation and Advanced Development of Emerging Technologies for Biospecimen Science (R33) Apply for RFA CA 13 004 Funding Number: RFA CA 13 004 Agency: National Institutes of Health Category: Education Health Funding Amount: $300,000 |
| Limited Competition Palliative Care Research Co Operative (PCRC) (U24) Apply for RFA NR 13 004 Funding Number: RFA NR 13 004 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Utilizing the PLCO Biospecimens Resource to Bridge Gaps in Cancer Etiology and Early Detection Research (U01) Apply for PAR 13 036 Funding Number: PAR 13 036 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Exceptional Unconventional Research Enabling Knowledge Acceleration (EUREKA) for Neuroscience and Disorders of the Nervous System (R01) Apply for RFA NS 13 007 Funding Number: RFA NS 13 007 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| AIDS and Cancer Specimen Resource (ACSR) (UM1) Apply for RFA CA 13 005 Funding Number: RFA CA 13 005 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Drug Discovery for Nervous System Disorders (R01) Apply for PAR 13 048 Funding Number: PAR 13 048 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Drug Discovery for Nervous System Disorders (R21) Apply for PAR 13 049 Funding Number: PAR 13 049 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Pain in Aging (R01) Apply for PA 13 058 Funding Number: PA 13 058 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Pain in Aging (R21) Apply for PA 13 059 Funding Number: PA 13 059 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Pain in Aging (R03) Apply for PA 13 060 Funding Number: PA 13 060 Agency: National Institutes of Health Category: Education Health Funding Amount: $50,000 |
| Administrative Supplements to NCI Funded Research Projects Funding to Advance Research on Cancers in Women (Admin Supp) Apply for PAR 13 067 Funding Number: PAR 13 067 Agency: National Institutes of Health Category: Education Health Funding Amount: $50,000 |
| Feasibility Studies to Build Collaborative Partnerships in Cancer Research (P20) Apply for PAR 13 068 Funding Number: PAR 13 068 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "PAR 12 297", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.